Navigation Links
The European Commission Grants Marketing Authorization for DIFICLIR™ (fidaxomicin) Tablets for Treatment of Clostridium difficile Infections
Date:12/12/2011

SAN DIEGO, Dec. 12, 2011 /PRNewswire/ -- Optimer Pharmaceuticals, Inc. (NASDAQ: OPTR) and Astellas Pharma Europe Ltd., a European subsidiary of Tokyo-based Astellas Pharma Inc. (Tokyo: 4503) announced today that the European Commission has granted Marketing Authorization (MA) for DIFICLIR™ (fidaxomicin) tablets for the treatment of adults with Clostridium difficile infections (CDI) also known as Clostridium difficile-associated diarrhea (CDAD). CDI is a significant problem in hospitals and long-term care facilities all over the world. EMA approval was based on two large, multi-national, Phase 3 clinical trials that demonstrated that DIFICLIR was as effective as oral vancomycin in treating CDI. DIFICLIR had a significantly lower rate of recurrence (including relapses) compared to vancomycin in the 30 days following treatment.  DIFICLIR is the only drug approved by the EMA proven to significantly lower the rate of recurrence of CDI compared to oral vancomycin. The clinical trials included patients over the age of 65 and those taking concomitant antibiotics to treat multiple infections.

"The European approval is a key step in making fidaxomicin more widely available to patients across the globe to treat this very serious disease," said Pedro Lichtinger, President and Chief Executive Officer of Optimer. "We believe we have obtained a very strong label recognizing the benefits of DIFICLIR versus vancomycin, including significant reductions in recurrence."

The European approval affirms the recent positive opinion from the Committee of Medicinal Products for Human Use (CHMP) and is based on two Phase 3 clinical trials that were conducted to ensure the safety and efficacy of 400mg/day DIFICLIR (fidaxomicin) tablets compared to 500mg/day oral vancomycin for 10 days in subjects with CDI. The first Phase 3 study was carried out in 629 subjects in No
'/>"/>

SOURCE Optimer Pharmaceuticals, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related medicine technology :

1. ULURU Inc. Extends the European Altrazeal® License to Include Australia and New Zealand
2. Ampio Pharmaceuticals Awarded European Patent that Strengthens Intellectual Property Protection for its key drug Ampion™
3. Avanafil Data Presented at the European Society of Sexual Medicine Meeting
4. European Medicines Agencys (EMA) Committee for Human Medicinal Products (CHMP)Tentatively Scheduled to Render an Opinion on PixuvriTM Marketing Authorization Application on January 19, 2012
5. CardioInsight Announces CE Mark Clearance and European Launch of the ECVUE™ Non-Invasive Electrocardiographic Mapping System
6. Omeros Announces Submission to European Medicines Agency of Paediatric Investigation Plan Letter of Intent for OMS302
7. Delcath Announces Agreement With European Institute of Oncology for Initial Launch of Hepatic Chemosat Delivery System in the European Union
8. X-ray Equipment - Top 5 European Markets
9. Amsterdam Molecular Therapeutics Receives Orphan Designation in the European Union for Hemophilia B Gene Therapy
10. RSB Spine, LLC, Announces European Patent Allowance
11. Vectibix® (Panitumumab) Granted Approval for Expanded Indications in the European Union
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/28/2015)... 28, 2015 Research ... addition of the "Investigation Report on China,s ... Developed by AstraZeneca plc, quetiapine (under ... drug for the treatment of schizophrenia. Approved by ... listed in the Catalogue of Drugs for the ...
(Date:8/28/2015)... 28, 2015 Research and ... the "Investigation Report on China,s Ranibizumab Market, 2012-2019" ... Novartis, ranibizumab was approved by CFDA to treat wet ... Lucentis, a product of Novartis, is available in the ... self- developed drug for the treatment of wet AMD ...
(Date:8/28/2015)... Perrigo Company plc ("Perrigo") (NYSE: PRGO ... (NASDAQ: MYL ) shareholder vote regarding its planned ... of Mylan,s offer to Perrigo shareholders have always been, ... careful reflection of the value available to Perrigo shareholders, ... Mylan has allowed its shareholders to consider," said ...
Breaking Medicine Technology:China Quetiapine Market Investigation Report 2010-2019 2Investigation Report on China's Ranibizumab Market, 2012-2019 2Perrigo Confident Its Shareholders Will Reject Mylan's Value Destructive Transaction 2Perrigo Confident Its Shareholders Will Reject Mylan's Value Destructive Transaction 3Perrigo Confident Its Shareholders Will Reject Mylan's Value Destructive Transaction 4Perrigo Confident Its Shareholders Will Reject Mylan's Value Destructive Transaction 5
... SAN MARINO, Calif. , July 6 ... of targeted genetic medicine, received a notice of allowance ... leading tumor-targeted gene delivery platform. The issuance of this ... follows on the heels of two major patent issuances ...
... N.J. , July 6 Nephros, Inc. (OTC Bulletin ... for therapeutic applications, infection control, and water purification, today reported that ... a standard component of its MRO portable reverse osmosis water treatment ... , ...
Cached Medicine Technology:Small, Smart, Stealth Nanoparticles Seek-and-Destroy Metastatic Cancers, as Epeius Biotechnologies Advances its Intellectual Property Estate With Additional U.S. Patents 2Small, Smart, Stealth Nanoparticles Seek-and-Destroy Metastatic Cancers, as Epeius Biotechnologies Advances its Intellectual Property Estate With Additional U.S. Patents 3Nephros and AmeriWater Announce Dual Stage Ultrafilters to be a Standard Component of MRO Series Water Treatment Systems 2Nephros and AmeriWater Announce Dual Stage Ultrafilters to be a Standard Component of MRO Series Water Treatment Systems 3Nephros and AmeriWater Announce Dual Stage Ultrafilters to be a Standard Component of MRO Series Water Treatment Systems 4Nephros and AmeriWater Announce Dual Stage Ultrafilters to be a Standard Component of MRO Series Water Treatment Systems 5
(Date:8/30/2015)... Auckland, NZ (PRWEB) , ... August 30, 2015 ... ... enterprise collaboration across platforms and devices, today announced it is a Silver Sponsor ... 1, 2015 at Sky City Convention Centre in Auckland, NZ. Throughout the event, ...
(Date:8/30/2015)... Raton, Fl (PRWEB) , ... August 30, 2015 , ... ... InHealth Media. Nutritional Products International and InHealth media is a global sales and ... , “We are extremely pleased to continue our business relationship with Mr. Reid Eckert, ...
(Date:8/29/2015)... ... August 30, 2015 , ... On September 30, 2015, the ... of the 10 regionally accredited Maricopa Community Colleges , will be hosting a ... students pursuing employment information and opportunities. , The Expo has expanded to much more ...
(Date:8/29/2015)... ... August 29, 2015 , ... Targeted therapies, made possible by ... of patients, according to a newly published report. Surviving Mesothelioma has more on ... , The authors of the new paper focus on several types of ...
(Date:8/29/2015)... , ... August 29, 2015 , ... ... angina, chronic obstructive pulmonary disease (including emphysema), or asthma, are at higher risk ... angina, previous heart attack, heart failure or heart-rhythm problems (arrhythmia or irregular heartbeat) ...
Breaking Medicine News(10 mins):Health News:AvePoint Showcases the Future of Enterprise Collaboration as Silver Sponsor of the Digital Workplace Conference in New Zealand 2Health News:AvePoint Showcases the Future of Enterprise Collaboration as Silver Sponsor of the Digital Workplace Conference in New Zealand 3Health News:AvePoint Showcases the Future of Enterprise Collaboration as Silver Sponsor of the Digital Workplace Conference in New Zealand 4Health News:Nutrition Guru Continues Relationship With Renowned Health and Wellness Company 2Health News:Estrella Mountain Community College Expo Offers ‘One-Stop’ for Employers and Students Seeking Internships, Jobs, Careers and Service Learning Opportunities 2Health News:Top Mesothelioma Researchers Highlight Targeted Therapies in New Report, According to Surviving Mesothelioma 2Health News:Heart Fit Clinic Sounds the Alarm on Forest Fire Smoke and Chronic Heart Disease in Calgary Area 2
... issue of Technology & Innovation, Proceedings of the ... bright future and enormous need for stem cell therapeutics ... and deadly diseases. http://www.ingentaconnect.com/content/cog/ti/2011/00000013/00000001 ... cell replacement" procedures to restructure damaged organs, tissues and ...
... ICU , Intensive care units are facing staffing ... A recent study, conducted by physicians from Beth Israel ... York, NY, studying 590 daytime admissions in two intensive ... address these staff shortages. In the study, no ...
... 8 to 18 consume an average of 13 hours of ... their white counterparts, according to a Northwestern University report, the ... by race and ethnicity. "In the past decade, the ... doubled for blacks and quadrupled for Hispanics," says Northwestern Professor ...
... researcher in the University of Cincinnati (UC) Department of ... from the Emergency Medicine Foundation to study the implementation ... (ED). The award will support the work of ... of Medicine. Ward has spent the past year focusing ...
... This release is available in French . Montreal, ... needs to be decriminalized, according to a new report published in ... and University of Windsor researchers, the study calls for sweeping changes ... "We must not only change our laws, we must also revamp ...
... Houston environmental engineer will test parts of Galveston Bay ... officials determine the best way to handle those pollutants., ... through a Texas Commission on Environmental Quality (TCEQ) grant ... last fall for similar research in the Houston Ship ...
Cached Medicine News:Health News:The future of stem cell applications challenging, bright 2Health News:Chest journal news briefs -- June 2011 issue 2Health News:Study: Stark differences in media use between minority and white youth 2Health News:Study: Stark differences in media use between minority and white youth 3Health News:Study: Stark differences in media use between minority and white youth 4Health News:Using simulation to model the implementation of electronic health records 2Health News:Dangerous and under the radar 2Health News:Dangerous and under the radar 3Health News:University of Houston researcher receives grant to study water pollutants 2
... anyone using the Farnsworth D15, L'Anthony desaturated test ... patients cannot avoid touching the color disks with ... Further, the disks are very easy to loose.,We ... in order to solve these problems. We have ...
... Farnsworth Dichotomous testing sets are designed ... The Farnsworth D15 test is used to ... Normal. The L'Anthony Desaturated test is much ... mild deficiency from Normal. Both of ...
... The NOW Strep A test is as easy ... minutes to results. Increase patient satisfaction with rapid ... can treat your patient immediately with the appropriate ... , ,Intended Use: ,The NOW® Strep A Test ...
12 mm single use, reloadable laparoscopic linear stapler with titanium staples....
Medicine Products: